Accelerating Preclinical TCE Development for Autoimmune Disease Therapies

Vivia Biotech offers comprehensive assays for TCE development in Autoimmune Diseases.

Ex Vivo Assay Using Whole Bone Marrow Environment to Investigate the Efficacy of Daratumumab in Multiple Myeloma

Vivia Biotech recently presented at the EHA Congress its novel ex vivo assay featuring daratumumab (DARA), a monoclonal antibody for treating Multiple Myeloma (MM).

B Cell Proliferation Assay for Autoimmune Disease Drug Activity

Vivia’s anti-proliferative assay provides the best conditions for patient-derived B cells ex vivo culture, allowing a wide variety of therapeutic compounds screening

TME Immunosuppression Assay: Enhancing Immuno-Oncology Development

The tumor microenvironment (TME) comprises of distinct cell types, each of which can assume a variety of phenotypes defined by the expression of multiple proteins. It contains tumor, stromal and several types of immune cells, irrigated by an altered vascular system and embedded in a dense extracellular matrix, which compromises its oxygen levels

TCE Assays Complying with FDA Recommendations in Patient Samples

Vivia Biotech is groundbreaking research in the field of T Cell Engager (TCE) through significant progress in ex vivo pharmacology studies for patients with hematologic malignancies

TILs ex vivo Expansion for Research Purposes

At Vivia Biotech, we specialize in producing TILs from diverse solid tumor indications, offering complete clinical information, comprehensive immunophenotyping, and potency assays conducted on cell lines

Advancing ADC Hit-to-Lead Compounds through Cutting-Edge Assays and Real Patient Samples in Native Environment

Vivia Biotech can profile your ADC compound by utilizing state-of-the-art assays within a native environment, and gaining access to real biological samples from patients, thereby streamlining the selection process for ADC Hit-to-Lead compounds

Ex vivo proliferation assays for CLL patient samples: optimal for BTK or PI3Kδ inhibitors

Vivia Biotech has developed accurate assays specifically tailored for characterizing the ex vivo pharmacological profile of your anti-proliferative CLL drug compounds, directly using authentic patient samples

FDA 2.0: Advancing Preclinical Development with Real Patient Samples and Cell-Based Assays

The FDA Modernization Act 2.0 is changing the scope of research allowing the use of other alternative methods to the use of animals in your non-clinical drug development, such as ex vivo cell-based assays, to investigate the safety and efficacy of your drugs

TILs Expansion and Killing Assays

Tumor Infiltrated Lymphocytes (TILs) in vitro expansion are innovative T Cell therapies in the field of immunotherapy with increasing promise against cancer.

Innovative Drug Interaction Studies

Drug combinations are critical in many diseases, including cancer. Synergistic drugs allow the use of lower doses in the treatment and therefore the adverse reactions would probably be reduced.

Select the Best Format for Your T Cell Engager

Vivia Biotech ex vivo assays in discovery phase can reveal big differences in T Cell Engagers (TCEs) formats.

Select AML samples with desired molecular profiles for your ex vivo experiments

Vivia Biotech can combine ex vivo activity with molecular data generated by NGS to better understand your drug activity in real AML patient samples

ADCC & CDC Activity Ex Vivo Assays at Physiological Levels

Vivia Biotech can scale CDC and ADCC assays at physiological levels using real native environment with autologous serum and effective E:T ratios with autologous NK Cells

Ex vivo Assays in MM Primary Patient Samples

Vivia Biotech can identify the best drugs for MM patient enhancing your MM drug profiling processes thanks to our improved and novel assays and to the access to biological samples from real patients...